These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 30718245)

  • 1. Impact of an Antimicrobial Stewardship Intervention on Within- and Between-Patient Daptomycin Resistance Evolution in Vancomycin-Resistant Enterococcus faecium.
    Kinnear CL; Patel TS; Young CL; Marshall V; Newton DW; Read AF; Woods RJ
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Institution-wide and Within-Patient Evolution of Daptomycin Susceptibility in Vancomycin-Resistant Enterococcus faecium Bloodstream Infections.
    Woods RJ; Patel TS; Nagel JL; Newton DW; Read AF
    Infect Control Hosp Epidemiol; 2018 Feb; 39(2):226-228. PubMed ID: 29331166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of Minimum Inhibitory Concentration in Clinical Outcomes of Enterococcus faecium Bacteremia Treated With Daptomycin: Is it Time to Change the Breakpoint?
    Shukla BS; Shelburne S; Reyes K; Kamboj M; Lewis JD; Rincon SL; Reyes J; Carvajal LP; Panesso D; Sifri CD; Zervos MJ; Pamer EG; Tran TT; Adachi J; Munita JM; Hasbun R; Arias CA
    Clin Infect Dis; 2016 Jun; 62(12):1514-1520. PubMed ID: 27045126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial susceptibility of bacteremic vancomycin-resistant Enterococcus faecium to eravacycline, omadacycline, lipoglycopeptides, and other comparator antibiotics: Results from the 2019-2020 Nationwide Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART).
    Tsai HY; Lee YL; Liu PY; Lu MC; Shao PL; Lu PL; Cheng SH; Ko WC; Lin CY; Wu TS; Yen MY; Wang LS; Liu CP; Lee WS; Shi ZY; Chen YS; Wang FD; Tseng SH; Chen YH; Sheng WH; Lee CM; Chen YH; Liao CH; Hsueh PR
    Int J Antimicrob Agents; 2021 Jul; 58(1):106353. PubMed ID: 33961991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of daptomycin non-susceptibility in colonizing vancomycin-resistant Enterococcus faecium isolates during daptomycin therapy.
    Lellek H; Franke GC; Ruckert C; Wolters M; Wolschke C; Christner M; Büttner H; Alawi M; Kröger N; Rohde H
    Int J Med Microbiol; 2015 Dec; 305(8):902-9. PubMed ID: 26454536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an
    Belley A; Arhin FF; Moeck G
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The importance of adjusting for enterococcus species when assessing the burden of vancomycin resistance: a cohort study including over 1000 cases of enterococcal bloodstream infections.
    Kramer TS; Remschmidt C; Werner S; Behnke M; Schwab F; Werner G; Gastmeier P; Leistner R
    Antimicrob Resist Infect Control; 2018; 7():133. PubMed ID: 30459945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilizing genomic analyses to investigate the first outbreak of vanA vancomycin-resistant Enterococcus in Australia with emergence of daptomycin non-susceptibility.
    Douglas AP; Marshall C; Baines SL; Ritchie D; Szer J; Madigan V; Chan HT; Ballard SA; Howden BP; Buising K; Slavin MA
    J Med Microbiol; 2019 Mar; 68(3):303-308. PubMed ID: 30663951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Continuous and Sequential Therapy among Veterans Receiving Daptomycin or Linezolid for Vancomycin-Resistant Enterococcus faecium Bacteremia.
    Britt NS; Potter EM; Patel N; Steed ME
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vancomycin-resistant Enterococcal Bloodstream Infections in Hematopoietic Stem Cell Transplant Recipients and Patients with Hematologic Malignancies: Impact of Daptomycin MICs of 3 to 4 mg/L.
    Chong PP; van Duin D; Bangdiwala A; Ivanova A; Miller WC; Weber DJ; Gilligan PH; Shea TC
    Clin Ther; 2016 Nov; 38(11):2468-2476. PubMed ID: 27771176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an
    Belley A; Lalonde-Séguin D; Arhin FF; Moeck G
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Daptomycin Dose on the Outcome of Vancomycin-Resistant, Daptomycin-Susceptible Enterococcus faecium Bacteremia.
    Chuang YC; Lin HY; Chen PY; Lin CY; Wang JT; Chen YC; Chang SC
    Clin Infect Dis; 2017 Apr; 64(8):1026-1034. PubMed ID: 28329222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1,2,4-Oxadiazole antimicrobials act synergistically with daptomycin and display rapid kill kinetics against MDR Enterococcus faecium.
    Carter GP; Harjani JR; Li L; Pitcher NP; Nong Y; Riley TV; Williamson DA; Stinear TP; Baell JB; Howden BP
    J Antimicrob Chemother; 2018 Jun; 73(6):1562-1569. PubMed ID: 29518208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daptomycin susceptibility testing and therapeutic use in enterococcal bloodstream infection (EBSI) in a setting with high rates of vancomycin-resistant Enterococcus faecium (VREfm).
    Kelly J; Tysall L; Dewar S
    J Antimicrob Chemother; 2022 Apr; 77(5):1432-1435. PubMed ID: 35165738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of risk factors and outcomes of daptomycin-susceptible and -nonsusceptible vancomycin-resistant Enterococcus faecium infections in liver transplant recipients.
    Lewis JD; Barros AJ; Sifri CD
    Transpl Infect Dis; 2018 Jun; 20(3):e12856. PubMed ID: 29427322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of different antimicrobial therapies on clinical and fiscal outcomes of patients with bacteremia due to vancomycin-resistant enterococci.
    Hayakawa K; Martin ET; Gudur UM; Marchaim D; Dalle D; Alshabani K; Muppavarapu KS; Jaydev F; Bathina P; Sundaragiri PR; Rajuri SD; Khatri J; Pogue JM; Lephart PR; Rybak MJ; Kaye KS
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3968-75. PubMed ID: 24798267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation and impact of an audit and feedback antimicrobial stewardship intervention in the orthopaedics department of a tertiary-care hospital: a controlled interrupted time series study.
    Tavares M; Carvalho AC; Almeida JP; Andrade P; São-Simão R; Soares P; Alves C; Pinto R; Fontanet A; Watier L
    Int J Antimicrob Agents; 2018 Jun; 51(6):925-931. PubMed ID: 29339298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daptomycin non-susceptible Enterococcus faecium in leukemia patients: Role of prior daptomycin exposure.
    DiPippo AJ; Tverdek FP; Tarrand JJ; Munita JM; Tran TT; Arias CA; Shelburne SA; Aitken SL
    J Infect; 2017 Mar; 74(3):243-247. PubMed ID: 27845153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005).
    Lee DK; Kim Y; Park KS; Yang JW; Kim K; Ha NJ
    J Biochem Mol Biol; 2007 Nov; 40(6):881-7. PubMed ID: 18047782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of daptomycin use with resistance development in Enterococcus faecium bacteraemia-a 7-year individual and population-based analysis.
    Egli A; Schmid H; Kuenzli E; Widmer AF; Battegay M; Plagge H; Frei R; Achermann R; Weisser M
    Clin Microbiol Infect; 2017 Feb; 23(2):118.e1-118.e7. PubMed ID: 27746397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.